ERBB2 and breast carcinoma: For instance, pharmacological inhibition of lysosomal V-ATPase overcomes trastuzumab (Anti-HER2 monoclonal antibody) resistance in breast cancer by impairing the elevated vesicular recycling of HER2 to the plasma membrane in trastuzumab-resistant cells [111].